FindTrial
Sign In

A clinical trial to find out if there is a role of persistent viral infection in patients with focal wasting of limbs diagnosed as Monomelic Amyotrophy (MMA) by their physicians/neurologist

To determine and search the role of persistent viral infection in patients of monomelic amyotrophy (MMA)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/07/009145
Enrollment
100
Registered
2017-07-27
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- All patients of monomelic amyotrophy (MMA) seen in Neurology department in the outpatient or admitted will be included in the study.

Interventions

None listed

Sponsors

Intramural Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients of monomelic amyotrophy (MMA) seen in Neurology department in the outpatient or admitted will be included in the study. The diagnosis is based on the following criteria[6]: (i) age at onset >18 years; (ii) disease duration of >4 years from the time of onset of weakness; (ii) evidence of lower motor neuron (LMN) involvement on neurological examination (weakness, atrophy and fasciculations); and (iv) electrophysiological evidence of LMN involvement on needle EMG examination.

Exclusion criteria

Exclusion criteria: Any of the following: 1 familial history of lower motor neuron disease (LMND); 2 deletion in the SMN1 gene or an expansion of CAG-repeats ( >40) in the androgen receptor gene; 3 history of diseases that may mimic LMND (acute poliomyelitis, spinal radiculopathy, diabetic amyotrophy, thyrotoxicosis or hyperparathyroidism); 4 clinical signs of UMN involvement [pseudobulbar symptoms, brisk jaw jerk, hyperreflexia or extensor plantar response]; 5 objective sensory signs on neurological examination; 6 tracheostomy or intermittent ventilatory assistance; 7 structural lesions (tumors, intervertebral disk herniation, vascular lesions, syringomyelia) on MRI or myelography of the spinal cord; and 8 motor conduction block on extensive standardized nerve conduction studies

Design outcomes

Primary

MeasureTime frame
The primary outcome studied will be the clinical progression, if any, measured by MRC (Medical Research Council) grading of power in the affected area, The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)Timepoint: The time points are 3 months, 6 months and 1 year—

Secondary

MeasureTime frame
The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS)Timepoint: 6 months and one year—

Countries

India

Contacts

Public ContactDeepti Vibha

All India Institute of Medical Sciences

deeptivibha@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026